LRMR Stock — Larimar Therapeutics Inc.: Cash, EV, Pipeline

Share price

$3.79

Market cap

$393.7M

Cash

$156.3M

Enterprise value

$237.4M

Balance sheet

Cash	$156.3M
Debt	$0.0M
Net cash	$156.3M
Enterprise value	$237.4M
Basic shares	103.9M shares
Fully diluted shares	104.7M shares
Fully diluted market cap	$396.9M
Cash per share	$1.50

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading LRMR daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 12 - Mar 26	CTI-1601	Phase 2	Friedreich Ataxia	—
Aug 12 - Sep 23	Nomlabofusp	Phase 3	Friedreich Ataxia; Friedreich's Ataxia	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Nomlabofusp

Phase 2 · Active Modality: fusion protein

Target FXN (frataxin)

Partnerships Indiana University (exclusive license, 2016; Wake Forest license expired Dec 2025)

Indications

Friedreich's ataxia (Phase 2)

Catalysts

— second half of 2026

Status note Subcutaneously administered recombinant FXN-delivery fusion protein (CPP platform). Breakthrough Therapy Designation granted Feb 2026; rolling BLA submitted (first module Jun 2026). Confirmatory global Phase 3 study with first dosing expected mid-2026.

Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Nomlabofusp
Lead indication	Friedreich Ataxia
Lead phase	Phase 3
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07778836	Phase 3	Recruiting	Sponsor	LRMR	—	Friedreich Ataxia; Friedreich's Ataxia	—
NCT06447025	Phase 2	Recruiting	Sponsor	LRMR	—	Friedreich Ataxia	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Larimar Therapeutics, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
RTW Investments	2,565,999	+1,065,999	0.07%	2026-08-14
Sphera Biotech	926,004	+926,004	0.40%	2026-08-14
ADAR1 Capital Management	272,745	+220,000	0.04%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

LRMR — Larimar Therapeutics Inc.